Anatara Lifesciences Ltd (ASX:ANR)
0.0090
0.00 (0.00%)
At close: Mar 27, 2026
Anatara Lifesciences Revenue
Anatara Lifesciences had revenue of 177.56K AUD in the half year ending December 31, 2025, a decrease of -34.90%. This brings the company's revenue in the last twelve months to 623.76K, down -30.27% year-over-year. In the fiscal year ending June 30, 2025, Anatara Lifesciences had annual revenue of 969.46K with 50.53% growth.
Revenue (ttm)
623.76K
Revenue Growth
-30.27%
P/S Ratio
4.56
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 969.46K | 325.43K | 50.53% |
| Jun 30, 2024 | 644.03K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Tissue Repair | 3.38M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 761.96K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| Invex Therapeutics | 229.08K |